海外市场拓展加速，开启增长新纪元 海外业务占比提升，毛利率同比增幅较大。2024Q1，公司综合毛利率为 31.0%， 同比增长 9.8 个百分点，主要系高毛利率的海外业务占营收比重提升所致； 2024Q1 净利率 11.6%，同比下降 2.1个百分点，主要系当期计提坏账准备增加， 导致信用减值损失较去年同期上升所致。一季度公司期间费用 13.9%，同比增 长 1.0个百分点，其中销售、管理、研发、财务费用率分别为 3.9%、6.0%、2.4%、 1.6%，同比分别-1.2、+0.4、-1.5、+3.3 个百分点，财务费用率上升主要系可 转债按实际利率法摊销影响所致。 发布股权激励计划，彰显业绩信心。4 月 9 日公司发布股权激励计划草案，本 次激励对象涉及公司董事、高管、中层管理人员和核心骨干共 114 人。解锁目 标为：以 2023年净利润为基数，2024年、2024-2025年、2024-2026 年净利 润增长（累计增长）率分别不低于 50%、275%、612.5%；对应 2024-2026 年 净利润目标分别为 1.53、2.30、3.44亿元，复合增速达 50.0%，彰显发展信心。 风险提示：原材料 ...

[ T able_StockInfo] 2024 年 04 月 19 日 证券研究报告•2023 年年报点评 持有 （维持） 当前价：27.10 元 信捷电气（603416）机械设备 目标价：——元（6 个月） | --- | --- | --- | --- | --- | |----------------------------------|---------|---------------------------------|--------|--------| | | | | | | | [Table_MainProfit] 指标 / 年度 | 2023A | 2024E | 2025E | 2026E | | 营业收入（百万元） | | 1505.05 1719.17 1967.84 2223.67 | | | | 增长率 | 12.73% | 14.23% | 14.46% | 13.00% | | 归属母公司净利润（百万元） | | 199.02 238.50 282.65 330.09 | | | | 增长率 | -10.37% | 19.84% | 18.51% | 16.78% | | 每 ...

Investment Rating - The report gives a "Hold" rating for the company, HaiXing Electric (603556) [8][26]. Core Insights - The company achieved a revenue of 4.2 billion yuan in 2023, representing a year-on-year growth of 26.9%. The net profit attributable to shareholders was 982 million yuan, up 47.9% year-on-year, while the non-recurring net profit was 940 million yuan, increasing by 60.1% [1][2]. - In Q4 2023, the company reported a revenue of 1.33 billion yuan, a 43.8% increase year-on-year, and a net profit of 310 million yuan, up 61.2% year-on-year [1]. - The company's new energy business saw significant growth, with revenue reaching 160 million yuan, a staggering 283.5% increase year-on-year [8][72]. - The report highlights the company's strong performance in overseas markets, particularly in Africa and Latin America, where it has secured various EPC projects [8][72]. Summary by Sections Company Overview - HaiXing Electric is a leading enterprise in the smart meter industry, focusing on energy transition with a diversified business model that includes smart electricity, smart distribution, and new energy products. The company has established a global presence, exporting to over 90 countries [30][72]. Financial Performance - The company reported a gross margin of 41.9% and a net margin of 23.4% in 2023, both showing improvements from the previous year. The Q4 margins were 24.3% and 8.2%, respectively [48]. - The smart electricity segment generated 3.6 billion yuan in revenue, growing by 23.9%, while the smart distribution segment achieved 410 million yuan, up 24.2% [48][72]. Revenue Forecast - The company expects revenues for 2024, 2025, and 2026 to be 5.38 billion yuan, 6.45 billion yuan, and 7.46 billion yuan, respectively, with net profit growth rates of 22.5%, 18.6%, and 18.2% [8][26]. Market Position - HaiXing Electric is positioned as a leading player in the domestic smart meter market, with a strong focus on expanding its overseas business and enhancing its product offerings in smart distribution and new energy sectors [8][72].

Investment Rating - The report initiates coverage with a recommendation to actively monitor the company, identified as a leading domestic manufacturer of home ventilators, with an expected compound annual growth rate (CAGR) of 17.4% in net profit over the next three years [9]. Core Insights - The global market for home ventilators is projected to reach approximately $11.17 billion by 2030, with a CAGR of 9% from 2023 to 2030. The domestic market is expected to grow significantly, reaching around 4.8 billion yuan by 2030, with a CAGR of 18% during the same period [2][7]. - The company has successfully increased its market share in the global home ventilator market from 4.5% in 2020 to 17.7% in 2022, positioning itself as the second-largest player following Philips [8][7]. - The company has a comprehensive product line in the respiratory health sector, with product quality comparable to leading international brands, and has made significant advancements in product innovation and iteration [3][7]. Summary by Sections Company Overview - The company is recognized as a leading domestic manufacturer of home ventilators, with a strong focus on expanding its overseas market presence [29][35]. - The company has demonstrated strong profitability, with a notable increase in the proportion of overseas business [41][50]. - The management team possesses extensive experience in the medical device industry, contributing to the company's growth and innovation [53][60]. Industry Analysis - The respiratory health care industry is characterized by a significant unmet demand, particularly in chronic diseases such as COPD and OSA, which are prevalent in China [2][66]. - The global market for chronic disease management is substantial, with significant opportunities for domestic manufacturers to capture market share [2][66]. - The recall of Philips ventilators has reshaped the market landscape, providing an opportunity for the company to expand its presence in the U.S. market [8][50]. Company Analysis - The company has established a full product line in the respiratory health sector, continuously innovating and upgrading its products [3][41]. - The collaboration with RH (3B) has facilitated the company's entry into overseas markets, enhancing its competitive position [50][8]. - The company’s product quality is increasingly comparable to that of international leaders, with ongoing improvements in both hardware and software aspects [3][41]. Financial Forecast - The company is expected to achieve a net profit of approximately 297.34 million yuan in 2025, with a projected growth rate of 18.52% [10][9]. - The revenue for 2025 is forecasted to reach 1.31 billion yuan, reflecting a growth rate of 16.83% compared to the previous year [10][9].

[2T0a2b4le年_I0n4du月str2y0In日fo ] 强于大市(维持) 证券研究报告•行业研究•医药生物 医药行业周报（4.15-4.19） 持续关注底部个股 投资要点 西南证券研究发展中心  [行Ta情bl回e_顾Su：m本m周ary医] 药生物指数下跌 1.7%，跑输沪深 300指数 3.6个百分点， [分Ta析bl师e_：Au杜th向or阳] 行业涨跌幅排名第 19。2024年初以来至今，医药行业下跌 15.7%，跑输沪深 300 指数 18.9 个百分点，行业涨跌幅排名第 28。本周医药行业估值水平 执业证号：S1250520030002 (PE-TTM)为 25倍，相对全部A股溢价率为78.6% (-3.2pp)，相对剔除银行后 电话：021-68416017 全部A股溢价率为33% (-1.6pp)，相对沪深300溢价率为 117% (-6.6pp)。本 邮箱：duxy@swsc.com.cn 周相对表现最好的是血液制品，上涨4.5%。 [行Ta业bl相e_对Qu指o数te表Pic现]  4月 15日晚，彭博新闻稿提及欧盟将调动国际采购工具IPI，对中国医疗器械 采购启动调查，以 ...

Investment Rating - The report maintains a "Hold" rating for the company, with a current price of 24.08 CNY and a target price not specified for the next 6 months [28][38]. Core Insights - The company achieved a revenue of 6.074 billion CNY in 2023, representing a year-on-year growth of 11.3%. The net profit attributable to the parent company was 412.88 million CNY, up 65.1% year-on-year [28][29]. - The overall gross margin for 2023 was 36.3%, an increase of 4.7 percentage points year-on-year, driven by a decrease in shipping costs [29]. - The company is experiencing robust growth in its B2C channel, with revenue reaching 4.94 billion CNY in 2023, a 14.0% increase year-on-year [23][30]. Financial Summary - Revenue projections for 2024-2026 are as follows: 7.629 billion CNY in 2024 (25.6% growth), 9.398 billion CNY in 2025 (23.2% growth), and 11.399 billion CNY in 2026 (21.3% growth) [11][33]. - The net profit attributable to the parent company is expected to grow to 521.22 million CNY in 2024, 650.02 million CNY in 2025, and 793.77 million CNY in 2026 [11][33]. - The company’s EBITDA is projected to increase from 479.27 million CNY in 2023 to 1.01256 billion CNY in 2026 [11][33]. Business Segments - The furniture segment generated 2.710 billion CNY in revenue in 2023, with a gross margin of 36.6%, while the home segment achieved 2.285 billion CNY with a gross margin of 37.2% [18][29]. - The pet segment saw a revenue increase of 37.3% year-on-year, reaching 518.54 million CNY, indicating strong market demand [30][29]. - The company is expanding its market presence in Europe and North America, with revenues of 3.73 billion CNY and 2.17 billion CNY respectively in 2023 [30].

Investment Rating - The report maintains a "Hold" rating for the company [6][5]. Core Insights - The company achieved a revenue of 540 million yuan in 2023, representing a year-on-year growth of 12.3%. However, the net profit attributable to shareholders decreased by 8.4% to 90 million yuan [19][5]. - The company’s comprehensive gross margin improved slightly to 29.9%, up 1.1 percentage points year-on-year, benefiting from low raw material prices, although new businesses have not yet achieved scale [5][19]. - The linear guide rail business has seen rapid growth, with sales revenue reaching 21.83 million yuan, a nearly fourfold increase year-on-year, indicating strong market acceptance and capacity release [20][11]. Summary by Sections Financial Performance - In Q4 2023, the company reported a revenue of 140 million yuan, a year-on-year increase of 27.6% and a quarter-on-quarter increase of 1.6%. The net profit for the same quarter was 15 million yuan, down 37.2% year-on-year and 26.8% quarter-on-quarter [19][5]. - The company’s expense ratio for 2023 was 11.5%, an increase of 1.9 percentage points year-on-year, with a significant rise in R&D expenses [2][5]. Business Growth - The smart CNC equipment segment grew by 38.1% year-on-year, while the rolling functional components revenue surged by 391.1%, contributing to stable overall revenue growth [5][19]. - The company anticipates a compound annual growth rate (CAGR) of 23% for net profit attributable to shareholders from 2024 to 2026, with projected profits of 110 million, 130 million, and 160 million yuan respectively [6][19]. Market Position - The rolling functional components are expected to become a new growth engine for the company, with the market for these components in China projected to reach 33 billion yuan, heavily reliant on imports for high-end products [20][11]. - The company has over 20 years of technical experience in metal materials and heat treatment, which supports its competitive position in the market [20][11].

[Table_StockInfo] 持有 2024年 04月 21日 （维持） 证券研究报告•2023年报及 2024年一季报点评 当前价：3 6.04元 贝达药业（300558） 医 药生物 目标价：— —元（6个月） 贝福替尼有望快速放量，创新管线稳步推进 投资要点 西南证券研究发展中心 [T ab业le绩_S总um结m：a公ry]司 发布 2023 年报和 2024 年一季报，2023 年实现营业收入 24.56亿元（+3.35%），归母净利润 3.48亿元（+139.33%），扣非后归母净利 [分Ta析bl师e_：Au杜th向or阳] 润 2.63 亿元（+768.85%）。2024 年一季度实现营业收入 7.36 亿元 执业证号：S1250520030002 （+38.40），归母净利润 0.98 亿元（+90.95%），扣非后归母净利润 0.9 亿元 电话：021-68416017 （+390.39%）。 邮箱：duxy@swsc.com.cn  贝福替尼有望快速放量，恩莎替尼一线 NDA 获 FDA 受理。2023年，赛美纳 [相Tab对le指_Q数u表ot现eP ic] 二线治疗适应症、一 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance above the market index over the next six months [24][33]. Core Insights - The company has demonstrated strong growth in both e-commerce and peripheral channels, with Q1 2024 revenue reaching 770 million yuan, a year-on-year increase of 46.4% [23]. - The company's net profit attributable to shareholders for Q1 2024 was 100 million yuan, reflecting a year-on-year growth of 28.1% [23]. - The e-commerce channel achieved revenue of 300 million yuan in Q1 2024, marking a significant year-on-year increase of 150.5% [2]. - The company is focusing on enhancing its brand presence through targeted promotions on platforms like Douyin, which has led to increased brand awareness and sales across various e-commerce platforms [2]. Summary by Sections Financial Performance - In Q1 2024, the company achieved a gross margin of 54.4%, up 7.5 percentage points year-on-year, benefiting from a higher proportion of high-margin products like probiotics [13]. - The total expense ratio was 39%, an increase of 9.8 percentage points year-on-year, with sales expenses rising significantly to 34.4% [13]. - The net profit margin for Q1 2024 was 13.4%, which is better than the full-year level of 2023 [13]. Revenue and Profit Forecast - Revenue projections for 2024-2026 are 2.72 billion yuan, 3.34 billion yuan, and 4.07 billion yuan, respectively, with corresponding net profits of 307 million yuan, 397 million yuan, and 504 million yuan [16]. - The expected EPS for 2024-2026 is 0.72 yuan, 0.93 yuan, and 1.18 yuan, with PE ratios of 25, 20, and 16 [24][34]. Market Expansion - The company is expanding its market presence in peripheral provinces, with revenue from these areas growing significantly [2]. - The focus on high-end product lines and the health series, particularly probiotics, is expected to enhance the company's market position and profitability [33].

[Table_StockInfo] 买入 2024年 04月 20日 （维持） 证券研究报告•2024年一季报点评 当前价： 30.06元 安琪酵母（600298） 食品饮料 目标价： ——元（6个月） 短期经营压力，全球布局明确 投资要点 西南证券研究发展中心 [T ab事le件_S：u公m司m发ar布y] 2024年一季报，一季度实现营业收入34.8亿元，同比增长2.5%， [分Ta析bl师e_：Au朱th会or振] 实现归母净利润3.2亿元，同比下滑9.5%。 执业证号：S1250513110001 电话：023-63786049  国内收入下滑，海外带动增长。1、分品类看，酵母及深加工产品、制糖产品分 邮箱：zhz@swsc.com.cn 别实现营业收入24.5亿元（+5.4%）、4亿元（-17.6%）。2、分区域看，国内、 分析师：夏霁 国外分别实现营业收入21亿元（-4.5%）、13.7亿元（+16.7%）。国内经营仍有 执业证号：S1250523070006 压力，国外增速相对领先。公司经营面向全球，在国内、全球酵母市占率分别 电话：021-68415380 约 55%、18%，出口至160 ...